Acurx Pharmaceuticals Files 8-K on Financials
Ticker: ACXP · Form: 8-K · Filed: May 13, 2025 · CIK: 1736243
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K on May 13th detailing financial results.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
Why It Matters
This 8-K filing provides an update on Acurx Pharmaceuticals' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- May 13, 2025 (date) — Date of earliest event reported
- 259 Liberty Avenue, Staten Island, NY 10305 (location) — Address of principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Acurx Pharmaceuticals?
The primary purpose of this 8-K filing is to report on Acurx Pharmaceuticals, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 13, 2025.
Where are Acurx Pharmaceuticals' principal executive offices located?
Acurx Pharmaceuticals' principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
In which state is Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. is incorporated in Delaware.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (917) 533-1469.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).